CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D009205: Myocarditis NIH

(Synonyms: Myocarditis)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (12)


Name (Synonyms) Correlation
drug27 2019-nCoV IgG/IgM Rapid Test Cassette Wiki 0.35
drug2215 Prediction Market Wiki 0.35
drug3315 laboratory biomarkers Wiki 0.35
drug3355 muscle ultrasound Wiki 0.35
drug517 CMR with T1 and T2 mapping Wiki 0.35
drug1032 Examinations for the research: Wiki 0.35
drug2091 Performing routine care (clinical and paraclinical tests) Wiki 0.35
drug2061 Passed infection of SARS-CoV-2 Wiki 0.35
drug982 Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care Wiki 0.35
drug410 Biological data Wiki 0.25
drug681 Clinical data Wiki 0.20
drug763 Convalescent plasma Wiki 0.08

Correlated MeSH Terms (15)


Name (Synonyms) Correlation
D009220 Myositis NIH 0.35
D018376 Cardiovascular Abnormalities NIH 0.35
D006330 Heart Defects, Congenital NIH 0.25
D009203 Myocardial Ischemia NIH 0.20
D054058 Acute Coronary Syndrome NIH 0.16
D007238 Infarction NIH 0.13
D054556 Venous Thromboembolism NIH 0.13
D020246 Venous Thrombosis NIH 0.11
D011655 Pulmonary Embolism NIH 0.10
D013923 Thromboembolism NIH 0.09
D004617 Embolism NIH 0.09
D013927 Thrombosis NIH 0.08
D018352 Coronavirus Infections NIH 0.03
D007239 Infection NIH 0.02
D045169 Severe Acute Respiratory Syndrome NIH 0.02

Correlated HPO Terms (8)


Name (Synonyms) Correlation
HP:0012819 Myocarditis HPO 1.00
HP:0100614 Myositis HPO 0.35
HP:0001627 Abnormal heart morphology HPO 0.25
HP:0001658 Myocardial infarction HPO 0.20
HP:0002625 Deep venous thrombosis HPO 0.11
HP:0002204 Pulmonary embolism HPO 0.10
HP:0001907 Thromboembolism HPO 0.09
HP:0001626 Abnormality of the cardiovascular system HPO 0.07

There are 8 clinical trials

Clinical Trials


1 Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19

COVID-19 outbreak is often lethal. Mortality has been associated with several cardio-vascular risk factors such as diabetes, obesity, hypertension and tobacco use. Other clinico-biological features predictive of mortality or transfer to Intensive Care Unit are also needed. Cases of myocarditis have also been reported with COVID-19. Cardio-vascular events have possibly been highly underestimated. The study proposes to systematically collect cardio-vascular data to study the incidence of myocarditis and coronaropathy events during COVID-19 infection.We will also assess predictive factors for transfer in Intensive Care Unit or death.

NCT04320017 COVID-19 Myocardial Injury Myocarditis Diagnostic Test: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care
MeSH:Myocarditis
HPO:Myocarditis

Primary Outcomes

Description: Viral myocarditis or myocardial infarction or stenosis detected with ST segment elevation or depression associated with troponine elevation and transthoracic echocardiography

Measure: Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay

Time: ECG and concomitant troponine at day 1 after admission at day 1, day 3 day 6 the first week after admission, and then at day 14 and before the patient is discharged (up to 20 days)

Secondary Outcomes

Description: Cardio-vascular events including but not limited to: myocardial infarction or stenosis, stroke, pulmonary embolism, deep vein thrombosis, ventricular dysfunctio, conduction disorders and sudden death

Measure: Description of cardiovascular outcomes in the cohort

Time: During hospital admission (up to 20 days)

Description: Biological biomarkers including but not limited to: baseline troponine T, D-dimers, NT-proBNP, creatinine phosphokinase, creatininemia, ionogram, renine-angiotensin aldosterone system profiling, glycemia (fasting), HbA1c, steroid profiling, lipid profiling

Measure: Prognosis role of baseline cardio-vascular caracteristics on patients survival

Time: 1st day of admission

Measure: Prediction of cardio-vascular events with baseline characteristics

Time: Baseline on first day of admission

Description: Biological markers including but not limited to: C reactive protein, procalcitonine, fibrinogen, interleukin-6

Measure: Characterization of inflammation on cardio-vascular outcomes

Time: Baseline and at day 3 day 6 day 14 and before patient is discharged (up to 20 days)

Description: clinical features at baseline: WHO performans status comorbidities and treatments Biological markers including but not limited to: full blood count, C reactive protein, procalcitonine, fibrinogen, interleukin-6, troponin and brain natriuretic peptide

Measure: Prognosis role of baseline clinico-biological caracteristics on patients transfer to ICU and survival

Time: Baseline and at day 3 day 6 day 14 and before patient is discharged (up to 20 days)

2 Screening of Cardiovascular Complications in Patients With COVID-19

Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.

NCT04335162 COVID Acute Coronary Syndrome Myocardial Infarction Myocarditis Venous Thromboembolism Deep Vein Thrombosis Pulmonary Embolism
MeSH:Pulmonary Embolism Myocardial Infarction Thrombosis Acute Coronary Syndrome Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis Myocarditis
HPO:Deep venous thrombosis Myocardial infarction Myocarditis Pulmonary embolism Thromboembolism Venous thrombosis

Primary Outcomes

Description: Incidence of cardiomyopathies and/or venous thromboembolism at day 28

Measure: Determine the incidence of cardiomyopathies and venous thromboembolism

Time: 28 days

Secondary Outcomes

Description: Incidence of mortality at day 28

Measure: Mortality

Time: 28 days

Description: Number of day of using mechanical ventilation for each patients

Measure: Duration of mechanical ventilation

Time: 28 days

Description: Incidence of shock at day 28

Measure: shock at day 28

Time: 28 days

Description: Number of day in intensive care unit

Measure: length of stay in the intensive care unit

Time: 28 days

3 Prospective Registry for Multimodal Assessment of Neuromuscular Pathology Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019 (Covid-19), who are admitted to the intensive care unit of the department of anesthesiology and intensive care medicine, or the department of neurology at Tübingen University Hospital.

NCT04367350 COVID Sars-CoV2 Corona Virus Infection Myositis Myocarditis Diagnostic Test: laboratory biomarkers Diagnostic Test: muscle ultrasound
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Myositis Myocarditis
HPO:Inflammatory myopathy Myocarditis Myositis

Primary Outcomes

Description: Elevation of creatine kinase during hyperacute phase of corona virus disease 2019 (Covid-19)

Measure: Rate of elevated creatine kinase in hyperacute phase

Time: 1 week

Secondary Outcomes

Description: Elevation of creatine kinase during hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)

Measure: Rate of elevated creatine kinase

Time: 24 months

Description: Two-peak elevation of creatine kinase during acute phase of corona virus disease 2019 (Covid-19)

Measure: Rate of two-peak elevation of creatine kinase during acute phase

Time: 30 days

Description: Presence of myositis-specific antibodies on admission, at two weeks, and at end of follow-up

Measure: Rate of myositis-specific antibodies

Time: 24 months

Description: Presence of antimyocardial antibodies on admission, at two weeks, and at end of follow-up

Measure: Rate of antimyocardial antibodies

Time: 24 months

Description: Level of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) assessed by the area under the curve (AUC)

Measure: Area under the curve (AUC) of elevated creatine kinase

Time: 24 months

Description: Maximal value of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)

Measure: Peak-levels of elevated creatine kinase

Time: 24 months

Description: Maximal value of troponin in the acute phase of corona virus disease 2019 (Covid-19)

Measure: Peak-levels of troponin

Time: 30 days

Description: Maximal value of urine myoglobin in the acute of corona virus disease 2019 (Covid-19)

Measure: Peak-levels of urine myoglobin

Time: 30 days

Description: Muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)

Measure: Rate of muscle hyperechogenicity

Time: 24 months

Description: Peak-muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)

Measure: Peak-muscle hyperechogenicity

Time: 24 months

4 Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 Cases During the Covid-19 Pandemic, Case Characteristics and Prognoses

To date, the effects of SARS-Cov-2 (Covid-19) on the myocardium and the role it plays in the evolution towards an acute myocarditis are badly understood. The current pandemic of this emerging virus is an opportunity to assess the proportion of acute myocarditis attributable to SARS-Cov-2(Covid-19) and to assess the clinical, biological and imaging presentations, by means of a national prospective multicentre hospital registry of cases of acute myocarditis.

NCT04375748 Acute Myocarditis Diagnostic Test: Performing routine care (clinical and paraclinical tests) Diagnostic Test: Examinations for the research:
MeSH:Myocarditis
HPO:Myocarditis

Primary Outcomes

Description: Estimate at hospital discharge, over a period of 6 months, the evolution of the proportion of positive SARS-COV-2 cases among patients hospitalized for acute myocarditis in Intensive Cardiac Care Unit or Intensive Care Unit (polyvalent, surgical or medical), in the 19 hospitals participating in the study.

Measure: Evolution of the proportion of positive SARS-COV-2 cases.

Time: 6 months.

Secondary Outcomes

Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort; Echocardiographic parameters: Volumes (mm3)

Measure: Ultrasound characteristics.

Time: 1 year

Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: diameters (mm)

Measure: Ultrasound characteristics.

Time: 1 year

Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular diastolic function (mm);

Measure: Ultrasound characteristics.

Time: 1 year

Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular systolic function (mm);

Measure: Ultrasound characteristics.

Time: 1 year

Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Left atrium volume (mm3);

Measure: Ultrasound characteristics.

Time: 1 year

Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Maximum velocity of tricuspid valve insufficiency;

Measure: Ultrasound characteristics.

Time: 1 year

Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence and quantification of a valvular regurgitation

Measure: Ultrasound characteristics.

Time: 1 year

Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence of a pericardial effusion

Measure: Ultrasound characteristics.

Time: 1 year

Description: Assess the short-term (30 days) and long-term (1 year) prognosis of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort. The 30-day prognosis will be defined in function to the outcome: A death, whatever the cause, A cardiovascular arrest with recovery, A cardiogenic shock, An acute lung oedema or One of the events cited above. The 1-year prognosis will be defined in function to the outcome: A death, whatever the cause, The need to resort to transplantation and/or chronic assistance, A rehospitalization for cardiovascular reasons (heart failure, painful relapse, recovered cardiac arrest, myocarditis relapse, ACS), A myocarditis relapse, or one of the events cited above. The 1-year prognosis will also be defined in function to the New York Heart Association (NYHA) class.

Measure: Assess prognosis of the acute myocarditis .

Time: The short-term (30 days) and long-term (1 year).

Description: Identify the factors associated with a 30-day and 1-year prognosis of cases of acute myocarditis cardiovascular (Terminal heart failure, Acute edema of the lung, Cardiogenic shock, Sudden death / Ventricular rhythm disorder Pulmonary embolism, Aortic dissection Infectious endocarditis Stroke) or no cardiovascular (Acute respiratory syndrome, septic shock of non-cardiac origin, cancer, Public road accident, end-stage respiratory failure, insufficiency, end-stage renal Failure)

Measure: The factors associated with acute myocarditis cases .

Time: The short-term (30 days) and long-term (1 year).

Description: Describe the biological parameters on admission and during the treatment (troponinemia (ng/ml)

Measure: Biological characteristics

Time: 1 year

Description: Describe the biological parameters on admission and during the treatment NtproBNP(pg/ml)

Measure: Biological characteristics

Time: 1 year

Description: Describe the biological parameters on admission and during the treatment CRP(mg/ml)

Measure: Biological characteristics

Time: 1 year

Description: Ventricular volumes (ml)

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Systole Diameter

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Diastole Diameter

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Longitudinal deformation of left ventricle;

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Longitudinal deformation of right ventricle;

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Total volume of left ventricular oedema

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Quantification of T2 before contrast agent

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Quantification of T1 before contrast agent

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Perfusion anomalies

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Total volume of early left ventricular alteration

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Total volume of late left ventricular alteration

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Quantification of T1 after contrast agent

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

Description: Presence of a pericardial effusion

Measure: Describe at the admission and during the treatment cardiac MRI parameters

Time: 1 year

5 Cardiac Involvement in Coronavirus (SARS-Cov-2) Infected Health Care Workers: The CCC Study

The study will analyze the prevalence of cardiac involvement of health care workers from the University Hospital of Salamanca (HUSA) who have overcome SARS-CoV-2 infection. Participants will undergo a clinical evaluation, electrocardiogram (EKG), cardiac magnetic resonance (CMR) and blood analysis including NT-proBNP, troponin, cellular and humoral immunity and genetics.

NCT04413071 SARS-CoV 2 COVID-19 Coronavirus Cardiac Magnetic Resonance Myocarditis Cardiac Anomaly Other: Passed infection of SARS-CoV-2
MeSH:Coronavirus Infections Myocarditis Heart Defects, Congenital Cardiovascular Abnormalities
HPO:Abnormal heart morphology Abnormality of the cardiovascular system Myocarditis

Primary Outcomes

Description: Prevalence of myocardial damage suggestive of myocarditis assessed by cardiac magnetic resonance

Measure: Myocarditis

Time: up to 3 months

Description: Prevalence of pericarditis assessed by clinical criteria

Measure: Pericarditis

Time: up to 3 months

Secondary Outcomes

Description: Prevalence of atrial fibrillation on EKG

Measure: Atrial fibrillation

Time: up to 3 months

Description: Prevalence of ischemic heart disease assessed by cardiac magnetic resonance

Measure: Ischemic heart disease

Time: up to 3 months

Description: Prevalence of dilatation of right heart chambers assessed by cardiac magnetic resonance

Measure: Dilatation of right heart chambers

Time: up to 3 months

Description: Prevalence of valvular heart disease assessed by cardiac magnetic resonance

Measure: Valvular hear disease

Time: up to 3 months

Description: Prevalence of prolonged QT interval on EKG

Measure: Rhythm disorders

Time: up to 3 months

6 Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children

The study objectives are to descript clinical, biological and echocardiographic features of an acute myocarditis in children in the context of COVID-19 and to identify the underlying mechanism : direct viral damage and/or inadequate host response risk.

NCT04420468 COVID-19
MeSH:Myocarditis
HPO:Myocarditis

Primary Outcomes

Description: Occurrence, description and time course of acute myocarditis

Measure: Acute myocarditis

Time: 7 days

Description: Occurrence, description and time course of multi-systemic inflammatory syndrome, features of Kawasaki disease

Measure: Multi-systemic inflammatory syndrome

Time: 7 days

Description: Occurrence, description and time course of features of Kawasaki disease

Measure: Kawasaki disease

Time: 7 days

Secondary Outcomes

Description: Results of SARS-CoV-2 screening either by PCR or antibodies serological assay

Measure: Results of SARS-CoV-2

Time: 7 days

7 IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION

Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy and prognostic relationships in apparently healthy subjects with no known heart disease. A further unknown relates to separation between healthy myocardium and the subclinical disease in several groups of patients with suspected cardiac involvement. Examples include patients with systemic inflammatory conditions, as well as patients with a recent COVID-19 infection.

NCT04444128 Myocarditis Heart Failure Myocardial Fibrosis Diagnostic Test: CMR with T1 and T2 mapping
MeSH:Myocarditis
HPO:Myocarditis

Primary Outcomes

Description: number of deaths

Measure: All-cause mortality

Time: 1 year

Description: number of deaths

Measure: All-cause mortality

Time: 5 years

Secondary Outcomes

Description: Number of participants with events including death due to heart failure and and hospitalisation due to Heart Failure

Measure: Heart Failure Outcome

Time: 1 year and 5 years

Description: Number of participants with death due to myocardial infarction, heart failure, arrhythmia or vascular events (pulmonary embolism, aortic dissection, stroke)

Measure: Cardiovascular Outcome

Time: 1 year and 5 years

Description: Number of participants with documented events including sudden cardiac death, appropriate ICD discharge, sustained VT

Measure: Arrhythmia Outcome

Time: 1 year and 5 years

8 MYocardial DOmmages Related to COVID-19

Myocardial injury, as assessed by elevation of cardiac troponins (Tnc), is frequent among patients with COVID-19. Although rare autopsy cases reported COVID-19 related myocardial inflammation, the origin of Tnc elevation is unknown to date. Several cardiac causes, such as myocarditis, non-ischemic myocardial injury (NIMI), or myocardial infarction (MI) may lead to Tnc kinetic. Our work will test the hypothesis that during SARS-Cov2 infection, the elevation of cardiac biomarkers could be linked to the occurrence of myocarditis.

NCT04498065 Covid19 Non Ischemic Myocardial Injury Myocardial Infarction Myocarditis Troponin Elevation Biological: Biological data Other: Clinical data
MeSH:Myocardial Infarction Myocarditis Infarction
HPO:Myocardial infarction Myocarditis

Primary Outcomes

Description: Myocardtitis diagnosis in patients COVID+ and troponin+

Measure: characterize the myocardial damage associated with CoV-2 SARS infection

Time: Through study completion, an average of 1 year


HPO Nodes


Protein Mutations 0
SNP 0